Targeting cannabinoid receptors as a novel approach in the treatment of graft-versus-host disease: Evidence from an experimental murine model

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 3, 2011, Pages 819-828

  Pandey, Rupal ^a   Hegde, Venkatesh L ^a   Nagarkatti, Mitzi ^a   Nagarkatti, Prakash S ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; DRONABINOL; GAMMA INTERFERON; INTERLEUKIN 2; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL EXPANSION; CELL PROLIFERATION; CELL TRANSFER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG TARGETING; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE INJURY; LIVER INJURY; LYMPHOID HYPERPLASIA; MORTALITY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RISK REDUCTION; SPLEEN CELL; TH1 CELL; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE MARROW CELLS; CELL PROLIFERATION; CHROMIUM RADIOISOTOPES; CYTOKINES; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GRAFT VS HOST DISEASE; HEMATOPOIESIS; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CANNABINOID; SPLEEN; SPLENOMEGALY; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; WEIGHT LOSS;

EID: 80052168226     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.182717     Document Type: Article

References (41)

1. Bortin MM, Horowitz MM, and Rimm AA (1992) Increasing utilization of allogeneic bone marrow transplantation. Results of the 1988-1990 survey. Ann Intern Med 116:505-512.
2. Broady R and Levings MK (2008) Graft-versus-host disease: suppression by statins. Nat Med 14:1155-1156.
3. Buckner CD and Clift RA (1989) Clinical studies of allogeneic marrow transplantation in patients with acute non-lymphoblastic leukaemia. Seattle Marrow Transplant Team. Bone Marrow Transplant 4(Suppl 3):82. (Pubitemid 20110689)
4. Center for Drug Evaluation and Research (2005) Guidance for industry: estimating the maximum starting dose in initial clinical trials for therapeutics in adult healthy volunteers. United States Food and Drug Administration, Rockville, MD. Available at: http://www.fda.gov/ohrms/dockets/98fr/02d-0492- gdl0002.pdf.
5. Chan PC, Sills RC, Braun AG, Haseman JK, and Bucher JR (1996) Toxicity and carcinogenicity of Δ9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundam Appl Toxicol 30:109-117.
6. Do Y, McKallip RJ, Nagarkatti M, and Nagarkatti PS (2004) Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-κB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J Immunol 173:2373-2382. (Pubitemid 39063093)
7. Ferrara JL and Deeg HJ (1991) Graft-versus-host disease. N Engl J Med 324:667-674.
8. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, Bouaboula M, Shire D, Le Fur G, and Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54-61.
9. Hakim FT, Sharrow SO, Payne S, and Shearer GM (1991) Repopulation of host lymphohematopoietic systems by donor cells during graft-versus-host reaction in unirradiated adult F1 mice injected with parental lymphocytes. J Immunol 146:2108-2115.
10. Hall W, Christie M, and Currow D (2005) Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol 6:35-42. (Pubitemid 40100410)
11. Hegde VL, Hegde S, Cravatt BF, Hofseth LJ, Nagarkatti M, and Nagarkatti PS (2008) Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells. Mol Pharmacol 74:20-33. (Pubitemid 351872155)
12. Hegde VL, Nagarkatti M, and Nagarkatti PS (2010) Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties. Eur J Immunol 40:3358-3371.
13. Jamontt JM, Molleman A, Pertwee RG, and Parsons ME (2010) The effects of Δ-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. Br J Pharmacol 160:712-723.
14. Jia W, Hegde VL, Singh NP, Sisco D, Grant S, Nagarkatti M, and Nagarkatti PS (2006) Δ9-Tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria. Mol Cancer Res 4:549-562. (Pubitemid 44341365)
15. Jiang S, Alberich-Jorda M, Zagozdzon R, Parmar K, Fu Y, Mauch P, Banu N, Makriyannis A, Tenen DG, Avraham S, et al. (2011) Cannabinoid receptor 2 and its agonists mediate hematopoiesis and hematopoietic stem and progenitor cell mobilization. Blood 117:827-838.
16. Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehnelt J, Petrosino S, Starowicz K, Steuder R, Schlicker E, Cravatt B, et al. (2007) Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 316:1494-1497. (Pubitemid 46906619)
17. Klein TW (2005) Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5:400-411.
18. Klein TW, Newton CA, Nakachi N, and Friedman H (2000) Δ9-Tetrahydrocannabinol treatment suppresses immunity and early IFN-γ, IL-12, and IL-12 receptor β2 responses to Legionella pneumophila infection. J Immunol 164:6461-6466.
19. Korngold R and Sprent J (1978) Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med 148:1687-1698. (Pubitemid 9084041)
20. Lombard C, Nagarkatti M, and Nagarkatti PS (2005) Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in Δ9-tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells. Leuk Res 29:915-922. (Pubitemid 40840719)
21. Mackie K (2006) Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 46:101-122.
22. Martin PJ, Hansen JA, Torok-Storb B, Durnam D, Przepiorka D, O'Quigley J, Sanders J, Sullivan KM, Witherspoon RP, and Deeg HJ (1988) Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant 3:445-456.
23. McKallip RJ, Lombard C, Fisher M, Martin BR, Ryu S, Grant S, Nagarkatti PS, and Nagarkatti M (2002a) Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100:627-634. (Pubitemid 34761128)
24. McKallip RJ, Lombard C, Martin BR, Nagarkatti M, and Nagarkatti PS (2002b) Δ9-Tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J Pharmacol Exp Ther 302:451-465. (Pubitemid 34787207)
25. McKallip RJ, Nagarkatti M, and Nagarkatti PS (2005) Δ-9- Tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol 174:3281-3289. (Pubitemid 40354031)
26. Michalski CW, Laukert T, Sauliunaite D, Pacher P, Bergmann F, Agarwal N, Su Y, Giese T, Giese NA, Bátkai S, et al. (2007) Cannabinoids ameliorate pain and reduce disease pathology in cerulein-induced acute pancreatitis. Gastroenterology 132:1968-1978. (Pubitemid 46695719)
27. Mori T, Nishimura T, Ikeda Y, Hotta T, Yagita H, and Ando K (1998) Involvement of Fas-mediated apoptosis in the hematopoietic progenitor cells of graft-versus-host reaction-associated myelosuppression. Blood 92:101-107.
28. Nagarkatti M, Rieder SA, Hegde VL, Kanada S, and Nagarkatti P (2010) Do cannabinoids have a therapeutic role in transplantation? Trends Pharmacol Sci 31:345-350.
29. Nagarkatti P, Pandey R, Rieder SA, Hegde VL, and Nagarkatti M (2009) Cannabinoids as novel anti-inflammatory drugs. Future Med Chem 1:1333-1349.
30. Pandey R, Hegde VL, Singh NP, Hofseth L, Singh U, Ray S, Nagarkatti M, and Nagarkatti PS (2009) Use of cannabinoids as a novel therapeutic modality against autoimmune hepatitis. Vitam Horm 81:487-504.
31. Pertwee RG (2009) Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156:397-411.
32. Pertwee RG and Ross RA (2002) Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 66:101-121. (Pubitemid 34743589)
33. Poynton CH (1988) T cell depletion in bone marrow transplantation. Bone Marrow Transplant 3:265-279.
34. Ramer R, Merkord J, Rohde H, and Hinz B (2010) Cannabidiol inhibits cancer cell invasion via up-regulation of tissue inhibitor of matrix metalloproteinases-1. Biochem Pharmacol 79:955-966.
35. Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J, Keyvanfar K, Montero A, Hensel N, Kurlander R, et al. (2006) High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 108:1291-1297. (Pubitemid 44232027)
36. Rieder SA, Chauhan A, Singh U, Nagarkatti M, and Nagarkatti P (2010) Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology 215:598-605.
37. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, and Farewell V (1986) Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314:729-735. (Pubitemid 16124386)
38. Via CS, Sharrow SO, and Shearer GM (1987) Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease. J Immunol 139:1840-1849. (Pubitemid 17141612)
39. Via CS and Shearer GM (1988) T-cell interactions in autoimmunity: insights from a murine model of graft-versus-host disease. Immunol Today 9:207-213.
40. Welniak LA, Blazar BR, and Murphy WJ (2007) Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 25:139-170. (Pubitemid 46697905)
41. Xenocostas A, Lapp WS, and Osmond DG (1987) Suppression of B lymphocyte genesis in the bone marrow by systemic graft-versus-host reactions. Transplantation 43:549-555. (Pubitemid 17065714)